Overview

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

Status:
Completed

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.

Phase:

Phase 3

Details

Lead Sponsor:

Ottawa Heart Institute Research Corporation

Collaborators:

Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Heart and Stroke Foundation of Canada

Treatments:

Anticoagulants
Apixaban
Coagulants
Dabigatran
Rivaroxaban